GERALDINE STEINAGEL: Open Payments
NPI 1255400487 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$525 in 36 payments from 7 companies in 2025. Trend: 2023 $823 · 2024 $710 · 2025 $525
Food & beverage: $525
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 24 | $295 |
| ABBVIE INC. | 3 | $63 |
| E.R. Squibb & Sons, L.L.C. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $14 |
Products named: FANAPT, HETLIOZ, VRAYLAR, COBENFY, TRINTELLIX, CAPLYTA, AUSTEDO XR, Auvelity.
Industry payments across NV — which companies pay providers there.
